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abstractOBJECTIVES: The possibility of newborn screening for fragile X syndrome is complicated by the
potential for identifying premutation carriers. Although knowing the child’s carrier status has
potential benefits, the possibility of late-onset disorders in carrier children and their parents
raises concerns about whether such information would be distressing to parents and
potentially more harmful than helpful. This study sought to answer this question by offering
voluntary fragile X screening to new parents and returning results for both the full mutation
and premutation FMR1 gene expansions. We tested the assumption that such information
could lead to adverse mental health outcomes or decision regret. We also wanted to know if
child age and spousal support were associated with the outcomes of interest.
METHODS: Eighteen mothers of screen-positive infants with the premutation and 15 comparison
mothers completed a battery of assessments of maternal anxiety, postpartum depression,
stress, family quality of life, decision regret, and spousal support. The study was longitudinal,
with an average of 3 assessments per mother.
RESULTS: The premutation group was not statistically different from the comparison group on
measures of anxiety, depression, stress, or quality of life. A subset of mothers experienced
clinically significant anxiety and decision regret, but factors associated with these outcomes could
not be identified. Greater spousal support was generally associated with more positive outcomes.
CONCLUSIONS: Although we did not find evidence of significant adverse events, disclosure of
newborn carrier status remains an important consideration in newborn screening policy.
WHAT’S KNOWN ON THIS SUBJECT: Parents
generally adapt well to newborn screening
results, but reactions to carrier status for
X-linked conditions are unknown.
WHAT THIS STUDY ADDS: Results suggest that
detection and disclosure of FMR1 newborn
carrier status may not result in significant
adverse events for mothers.
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Fragile X syndrome (FXS) is the most
common inherited form of intellectual
disability. Because physical features
are not evident at birth, FXS must be
detected through abnormalities in
development or behavior during
childhood. Parents typically
experience an extended “odyssey”
before FXS is diagnosed.1,2 The
average age of diagnosis is 36 months
for boys and later for girls, because
females are usually more mildly
affected.3 As a result, many children
with FXS have delayed opportunities
to participate in early-intervention
programs.4 In addition, as many as
25% to 30% of families have a second
child with FXS before the diagnosis of
the first child.3
Newborn screening is the only way all
children with FXS could be identified
early. However, FXS does not currently
meet criteria for inclusion in the
Recommended Uniform Screening
Panel by the Secretary’s Discretionary
Committee on Heritable Disorders in
Newborns and Children5 for 2 primary
reasons: (1) it is not considered
“medically actionable” and no studies
have shown that early intervention
significantly impacts development and
behavior and (2) no studies have
determined the costs or feasibility of
conducting high-through-put
screening in a state health laboratory.
Among the issues evoked by
screening for FXS in newborns, one of
the most concerning is the incidental
detection of carriers.6 The normal
FMR1 gene typically contains ,45
repetitions of the nucleotides
cytosine and guanine in CGG triplets,
a number that typically remains
stable across generations. Individuals
with expansions of 55 to 200 repeats
are premutation carriers. This repeat
length is unstable and can further
expand in future generations, causing
female carriers to be at risk of having
children of either gender with the full
mutation (.200 CGG repeats),
associated with FMR1 methylation
and transcriptional silencing,
resulting in FXS.
A DNA-based screening test for FXS
would also identify carrier infants.
This information could be useful to
parents, informing them of their
reproductive risk of having a child
with FXS and alerting them to
possible future health problems.
Although the American Academy of
Pediatrics and the American College
of Medical Genetics and Genomics7,8
do not recommend routine carrier
testing for minors, both acknowledge
that if carriers are detected in
newborn screening, it should be
disclosed to parents. Parents of
children with FXS strongly support
carrier disclosure,9,10 and a majority
of parents in the general population
accepted the possibility of carrier
detection in 2 pilot studies.11,12 But
disclosure of FMR1 carriers is
controversial because carrier status is
associated with risk of health,
cognitive, and emotional problems.13
Female carriers are at risk of primary
ovarian insufficiency,14 and both
genders are at risk of fragile
X–associated tremor ataxia
syndrome.15,16 Some carriers are also
at risk of learning problems and brain
function abnormalities,17,18 autism
spectrum features,19 and depression
or anxiety disorders.20–22 Thus, if
newborn screening for FXS were to
identify carrier children, it would
imply that they and the carrier parent
may be at increased risk of
developmental, behavioral, and
medical concerns.
Learning about carrier status could
increase the risk of anxiety,
depression, or stress, especially for
mothers. Postpartum depression and
anxiety are relatively common in the
general population.23–25 Females are
generally more likely to experience
depression than males,26 and
mothers with the premutation are at
risk of elevated depression and
anxiety, risks that could be
exacerbated by disclosure of their
infant’s carrier status.20–22 Research
on the impact of parents’ learning
that their healthy-appearing newborn
has a disorder provides mixed
evidence of increased depressive
symptoms or anxiety (eg, refs 27–31).
This finding may be due to evidence
that other factors such as lower
income, minority status, and lack of
social support are also strongly
associated with adverse mental
health outcomes.32
Although much has been written
about public attitudes toward the
return of genomic research findings,
most data come from hypothetical
studies.33 We recently completed
a multisite fragile X newborn
screening pilot study on the basis of
the assumption that research
studying the experiences of offering
testing and communicating results is
needed to fully understand benefits
and harms. We previously reported
acceptance rates and reasons for
accepting or declining screening,12
prevalence of FMR1 premutation
expansions,34 fathers’ participation in
the consent process,35 examples of
how the identification of a target child
can lead to identifying other family
members,36 and the development and
evaluation of a brochure to support
informed decision-making about
study participation.37,38
Here we report findings from an
assessment of maternal reactions to
the disclosure of their child’s FMR1
carrier status after newborn screening.
Our primary goal was to determine
whether these mothers experienced
adverse mental health outcomes
(stress, anxiety, depressive symptoms,
low quality of life), whether they
regretted the decision to participate,
and how adaptation over time varied
as a function of the child’s age or the
availability of spousal support.
METHODS
Setting and Procedures
The study was conducted in 3
university-based hospitals in North
Carolina, California, and Illinois. Study
recruitment procedures12 and
laboratory methods34 are detailed in
previous reports and briefly
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summarized here. Recruitment
processes varied slightly at each
hospital; but in general, shortly after
birth, families were approached by
a trained recruiter who asked if they
would be willing to hear about
a research project, to which most
families agreed. Families were given
brief written information and a short
verbal overview of the study. Those
who expressed interest were given
much more detailed information by
the recruiter, including the
comprehensive consent form.
Approximately halfway through the
project a new brochure was
developed to support informed
decision-making37,38 and was used at
all 3 sites. The brochure included
a section on what it means to be
a “fragile X carrier,” addressed the
implications of carrier status for both
newborns and parents, and made it
clear that carrier detection was
a much more likely outcome than the
detection of children with FXS.
Across the 3 sites, ∼20 374 families
were approached, and of those, 19 951
(97.9%) agreed to hear about the study.
Of those, 63.7% (12 709) agreed to
have their infant screened. One infant
screened positive for a full mutation
(not included in this article) and
45 screened positive for a premutation
allele, including 2 sets of twins.
Families of screen-positive children
were called by a genetic counselor,
pediatrician, or medical geneticist on
the research team, notified of results,
and offered a genetic counseling
appointment and confirmatory
testing. During this visit, families
were counseled about the potential
adult-onset health implications of
carrier status. Thirty infants had the
confirmatory testing. Of these, 2 were
found not to be carriers. Sixteen
families did not have confirmatory
testing for the following reasons:
declined genetic counseling (n = 3),
failed to show for the appointment
(n = 2), declined repeat testing of the
infant (n = 3), or were unable to be
reached via phone or mail (n = 8).
All families whose positive screening
result was confirmed (n = 28) were
invited to join the longitudinal
component of the study. Three
declined participation or were unable
to be reached to schedule a visit.
Twenty-three families (26 infants)
participated in at least 1 longitudinal
assessment, but 5 mothers did not
participate in the family assessments,
leaving a total of 18 mothers of
premutation infants reported here.
Fifteen mothers whose infants
screened negative who were matched
with the screen-positive group
on ethnicity, language, education,
and income were recruited as
a comparison group.
Because a substantial number of
parents did not participate in the
follow-up study, we compared
screen-positive participants and
nonparticipants on 5 variables
(maternal age, marital status, race/
ethnicity, maternal education, and
CGG repeat length of the identified
child) using t tests for continuous
variables (maternal age, CGG repeat
range) and x2 test for categorical
variables (marital status, race/ethnicity,
maternal education). The results are
shown in Table 1. No significant
differences were detected between the
groups on any of these variables.
The following 5 well-validated
measures were used to determine
whether mothers experienced
adverse outcomes and if they were
satisfied with their decision to
participate: (1) the 36-item short
form of the Parenting Stress Index39;
(2) the Spielberger State-Trait Anxiety
Inventory40; (3) the Edinburgh
Postnatal Depression Scale41; (4) the
Quality of Life Inventory (QOLI)42;
and (5) the Decision Regret Scale.43
The Emotional Intimacy Subscale of
the Personal Assessment of Intimate
Relationships Inventory44 was used
to assess spousal support.
Data Analysis
Data were collected at 1 to 7
occasions. The primary reason for this
variation was length of time in the
study, which lasted ∼4 years. The
family with 7 assessments was one
of the first identified, whereas families
with only 1 assessment mostly were
those identified toward the end of the
funding period. The mean number
of assessments was 3.1 for the
screen-positive group and 3.0 for the
comparison group. The 3 primary
research questions were as follows:
(1) whether mothers of screen-
positive children reported elevated
stress, anxiety, depression, or low
quality of life compared with mothers
in the comparison group; (2) whether
these mothers experienced significant
regret about their decision to
participate in the study; and (3) the
extent to which spousal support and
age of the child were related to the
outcomes measured. We first tested
3-way interactions of category
(premutation versus those who
screened negative)3 spousal support3
child age. Finding no evidence for
higher order effects, we retained only
the 2-way interactions. The initial
models also included tests of nonlinear
(quadratic) change over time, but
there was no evidence that such
trends existed, so all models were
simplified to include only linear terms.
We treated the models as 2-level,
random-intercept hierarchical linear
models with time nested within family.
Random effects are commonly used to
estimate and control nonindependence
in a model that arises from clustering
of data45; in this case, data were
clustered within participants, resulting
from repeated measurements over
time. Given our relatively small sample
size, we used the Kenward-Roger46
adjustment to the degrees of freedom
to test model parameters.
RESULTS
Models were conducted testing
group differences and interaction
effects of child’s age and spousal
support on stress, depression,
anxiety, quality of life, and decision
regret. Parameter estimates are
presented in Table 2.
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Parenting Stress
Across all assessments, the mean
total Parenting Stress Index score was
61.8 for mothers of children with the
premutation and 63.1 for mothers of
comparison children. A score $91 is
considered clinically significant and
scores of 86 to 91 are considered
above normal, so both groups were
well within the typical range. Stress
scores did not differ significantly by
group (premutation versus
comparison) or child age. Spousal
support was strongly associated with
total stress; mothers reporting high
levels of spousal support reported
lower stress. No interaction effects
were detected, indicating that spousal
support and child age were not
differentially associated with stress in
premutation versus comparison
mothers. Across all assessments, 6%
of mothers of children with the
premutation and 7% of mothers of
comparison children had at least 1
stress assessment in the clinically
significant range.
Maternal Depression
Across all assessments, the mean
Edinburgh Postnatal Depression Scale
score was 4.1 for mothers of children
with the premutation and 5.3 for
mothers of comparison children.
A score $10 is considered clinically
significant, so both groups were well
within the typical range. Depression
scores did not differ significantly by
group (premutation versus
comparison) or child age. Spousal
support was strongly associated
with depression; mothers who
perceived greater support reported
fewer depressive symptoms.
A significant interaction effect was
detected; spousal support was
differentially associated with stress in
premutation versus comparison
mothers. Across all assessments 12%
of mothers of children with the
premutation and 15% of mothers of
comparison children had at least 1
depression score in the clinically
significant range.
Maternal Anxiety
Across all assessments, the mean
State-Trait Anxiety Inventory score
was 34.3 for mothers of children with
the premutation and 31.7 for mothers
of comparison children. A score$45 is
considered clinically significant, so the
mean scores of both groups were
well within the typical range.
Maternal anxiety did not differ
significantly by group (premutation
versus comparison) or child age.
Spousal support was not directly
associated with anxiety, nor was
a significant group 3 support
interaction detected. However,
across all assessments, 29% of
mothers of children with the
premutation and 7% of mothers
of comparison children had at least
1 anxiety assessment in the
clinically significant range.
Quality of Life
Across all assessments, the mean
QOLI score was 46 for mothers of
children with the premutation and
47.8 for mothers of comparison
children. A score ,40 is considered
significantly low, so both groups
were within the typical range. QOLI
ratings did not differ significantly
by group (premutation versus
comparison). Child age was
significantly associated with QOLI
scores; mothers of younger children
reported lower QOLI ratings than
mothers of older children, but no
group 3 age interaction was found.
We did not find a main effect for
spousal support but did find a
significant group 3 support
interaction. Spousal support was
more important in predicting
quality of life for mothers of
children with the premutation
than for comparison mothers.
Across all assessments, 42% of
mothers of children with the
premutation and 38% of mothers
of comparison children had at least
1 assessment with a low quality-of-
life rating.
Decision Regret
The Decision Regret Scale is a 5-item
measure designed to assess “remorse
or distress over a decision”43
(p 281). Here the decision for mothers
was whether to have their child
screened for the FMR1 expansion.
Each item (eg, “It was the right
TABLE 1 Comparison of Participants and Nonparticipants in the Longitudinal Study on Selected
Demographic Variables
Variable Participants Nonparticipants P
Mothers
n 20 24 .23
Mean age (SD; range), y 30.6 (5.8; 18–44) 28.6 (4.99; 21–37)
Marital status, %
Married 52 48 .44
Divorced/separated 17 36
Never married 22 12
Unknown 9 4
Race/ethnicity, %
White 46 59 .97




High school or less 9 16 .61
Some college 39 40
College degree 26 28
Advanced degree 26 12
Unknown 0 7
Child
n 23 16 .93
Mean CGG repeat range (SD; range) 68.1 (17.8; 55–129) 67.6 (19.4; 55–129)
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decision”) is rated on a scale from 1
(strongly agree) to 5 (strongly
disagree). Because some items are
stated positively (eg, “It was the
right decision”) and some negatively
(eg, “I regret the choice that was
made”), we reverse-scored the positive
items so that a higher score indicated
greater regret. The authors suggest
converting scores to a 0 (no regret) to
100 (high regret) scale by subtracting
1 from each item, multiplying by 25,
and summing the items. Across all
assessments, the mean converted
score was 32.3 (range: 0–100) for
mothers of children with the
premutation and 5.7 (range: 0–25) for
mothers of comparison children.
Regret scores were significantly higher
for mothers of children with the
premutation. The group differences
were almost entirely accounted for
by 2 mothers, one who reported
high (90–100) regret at each
assessment occasion and a second
who was in the 75–80 range each
time. Decision regret was not
associated with child age or spousal
support, and no interaction effects
were found.
DISCUSSION
underThe detection of FMR1 carriers
by FXS screening in newborns and
its potential for harm and benefits have
been discussed extensively, but until
now concerns have been speculative.
Here we report findings from the
first study to offer FXS newborn
screening, return carrier results to
parents, and follow mothers of
infants to determine adaptation and
reactions over time. Our primary
goal was not to provide evidence that
screening was beneficial but rather
to attempt to detect significant
potential harms.
We found no group differences in the
domains assessed: depression,
anxiety, stress, or quality of life.
Mothers of screen-positive infants as
a group were no different from
a comparison group of mothers of
screen-negative infants on any
measure, both groups were well
within the range of typical scores,
and, with the exception of maternal
anxiety, there were no differences in
the number of mothers with clinically
significant scores. Six (29%)
mothers of children with the
premutation had at least 1 anxiety
assessment in the clinically significant
range, compared with only 2
comparison mothers. An analysis of
interviews and other scores with
these 6 mothers reveals a complex
picture, not easily leading to
a generalized explanation. Three of
the mothers had consistently low
regret scores, 2 had high regret. Four
of the 6 mothers had children with
the premutation who were showing
developmental or behavioral
problems, and 3 of the 6 had 2
children with the premutation
(2 sets of twins and 1 mother had
a second child with the premutation
during the study). Three mothers
were premutation carriers and thus
potentially at risk of elevated anxiety.
These observations suggest that
maternal anxiety is a complex and
multifaceted construct, likely
influenced by child and parent
characteristics, genetic factors, family
context, and spousal support.
Consistent with previous literature,
we found that mothers who reported
higher levels of spousal support had
lower stress and lower depression
scores than mothers who reported
lower levels of support. We did find
significant interaction effects,
showing that high spousal support
was more strongly associated with
lower depression and higher quality
of life in mothers of carrier infants
than in mothers of comparison
children.
We found significant group
differences in decision regret.
Mothers of infants with the
premutation expressed greater regret
about study participation than did
mothers of comparison children.
Comparison-group mothers had
nothing to regret, and thus most of
their scores were near zero. Most
mothers of identified children were
less likely to strongly agree with the
positively worded items, but their
average responses remained in the
positive range; a group mean of 50
would indicate an average neutral
score, and the premutation group
average was 32.3. But mothers of
identified children were generally
more ambivalent about the study and
perhaps still uncertain as to their
ultimate assessment of benefit or
harm. Two mothers clearly wished
that they had not participated in the
study. Although the written materials,
including the consent form, and
conversations with the recruiter
clearly specified the possibility of
carrier detection, the setting and
timing of recruitment (a few hours
after birth) may not have allowed
sufficient time for these mothers to
give full consideration to the study. As
such, it is possible that these and
other mothers had some residual
regret or at least uncertainty as to
whether study participation is
TABLE 2 Parameter Estimates (SEs) for Total Stress (Parenting Stress Index), Depression
(Edinburg Postnatal Depression Scale), Anxiety (Spielberger State-Trait Anxiety Scale),
Quality of Life (QOLI), and Decision Regret (Decision Regret Scale)
Effect Total Stress Depression Anxiety Quality of Life Decision Regret
Intercept 62.7 (2.8) 4.4 (0.9) 35.5 (1.8) 47.3 (2.2) 2.2 (0.3)
Group 20.8 (4.2) 0.4 (1.3) 24.4 (2.7) 1.9 (3.3) 20.9 (0.4)*
Age 0.3 (0.2) 20.2 (0.1) 0.03 (0.2) 20.3 (0.1)* 20.01 (0.01)
Spousal support 214.4 (3.9)*** 23.7 (1.2)** 27.1 (2.9) 10.0 (2.8) 20.2 (0.3)
Group 3 age 20.2 (0.3) 0.1 (0.2) 0.1 (0.3) 0.1 (0.3) 0.01 (0.02)
Group 3 support 7.6 (6.2) 5.2 (2.3)* 6.9 (4.4) 211.0 (4.7)* 0.02 (0.5)
Age 3 support 0.2 (0.2) 20.3 (0.2) 20.2 (0.2) 0.3 (0.1) 0.00 (0.01)
*P , .05, **P , .01, ***P , .001.
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something they would agree to if they
had the opportunity to reconsider
their decision.
Our findings should be interpreted
with some caution for several
reasons. The first and most
important limitation is potential bias
in the study sample due to lack of
participation in follow-up by
a number of screen-positive families.
To partially address this concern, we
compared participants and
nonparticipants on several variables
(maternal age, marital status, race/
ethnicity, maternal education, and
CGG repeat length of the identified
newborn) and found no group
differences. These findings increase
confidence in our conclusions, but
we acknowledge that we still do not
know why some families did not
participate. Some may have been
unconcerned about carrier status
and chose not to participate because
it did not seem immediately
important or relevant. Others may
not have participated because of
adverse events or decision regret.
A second limitation is the possibility
that the study was not sufficiently
powered to detect significant group
differences. Although possible, the
absolute differences between the
groups were quite small, so it is
unlikely that a larger sample would
have affected the findings. However,
the small sample size meant that we
were not able to assess factors other
than child age or spousal support
associated with variability in the
outcomes measured.
Despite these limitations, we found
little evidence that the disclosure
of carrier status in newborn
screening for FXS, when conducted
under a voluntary consent protocol
with consent obtained from both
parents when possible, significantly
elevates the risk of stress,
anxiety, depression, or low quality
of life. Some mothers regretted
participating in the study, suggesting
that the newborn setting may
hinder full understanding of the
implications of consent. In addition,
some mothers experienced
elevated anxiety, although we
cannot unequivocally demonstrate
that learning their child’s carrier
status was the cause.
Several features of FXS currently
make it unsuitable for inclusion on
mandatory newborn screening
panels, a situation that will remain
until data show that earlier
identification results in measurable
benefits for children. Until then,
this study suggests that the
disclosure of newborn carrier status,
although an important consequence
to consider when making policy
decisions about screening, consent,
and follow-up services, may not have
a significantly negative impact on
mothers of identified children,
especially in families where spousal
support is adequate.
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